Medlab Clinical (ASX:MDCDA) - Stock Price, News & Analysis

MDCDA Stock Overview

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia.

About the company

MDCDA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 27.38% per year

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Earnings are forecast to decline by an average of 21.4% per year for the next 3 years

Does not have a meaningful market cap (A$25M)

+ 2 more risks

Medlab Clinical Limited Competitors

Noxopharm

ASX:NOX

AU$20.5m

AdAlta

ASX:1AD

AU$15.5m

Cynata Therapeutics

ASX:CYP

AU$47.6m

Radiopharm Theranostics

ASX:RAD

AU$37.0m

Price History & Performance

Summary of all time highs, changes and price drops for Medlab Clinical
Historical stock prices
Current Share Price	AU$10.50
52 Week High	AU$13.00
52 Week Low	AU$10.01
Beta	1.61
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	3.96%

Recent updates

Shareholder Returns

	MDCDA	AU Biotechs	AU Market
7D	4.0%	0.7%	0.9%
1Y	n/a	10.0%	9.6%

Return vs Industry: Insufficient data to determine how MDCDA performed against the Australian Biotechs industry.

Return vs Market: Insufficient data to determine how MDCDA performed against the Australian Market.

Price Volatility

Is MDCDA's price volatile compared to industry and market?
MDCDA volatility
MDCDA Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.5%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.2%

Stable Share Price: MDCDA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine MDCDA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2012	n/a	Sean Hall	www.medlab.co

Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia. Its lead drug candidate includes NanaBis, an oro–buccal administered equimolar tetrahydrocannabinol (THC) and cannabidiol (CBD) formulation as monotherapy, which is in phase 3 multi-centre, quadruple-blind, randomized- withdrawal active, and placebo-controlled clinical study for the management of opioid-requiring–bone–pain due to metastatic cancer. The company also develops NanoCelle, a patented sub-micron drug delivery platform that enhances drug solubility issues and enables faster absorption and metabolism of active ingredients.

Medlab Clinical Limited Fundamentals Summary

How do Medlab Clinical's earnings and revenue compare to its market cap?
MDCDA fundamental statistics
Market cap	AU$25.12m
Earnings (TTM)	-AU$11.99m
Revenue (TTM)	AU$4.47m

5.6x

P/S Ratio

-2.1x

P/E Ratio

Is MDCDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MDCDA income statement (TTM)
Revenue	AU$4.47m
Cost of Revenue	AU$2.78m
Gross Profit	AU$1.69m
Other Expenses	AU$13.68m
Earnings	-AU$11.99m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-5.25
Gross Margin	37.82%
Net Profit Margin	-268.08%
Debt/Equity Ratio	0%

How did MDCDA perform over the long term?

See historical performance and comparison

Medlab Clinical ASX:MDCDA Stock Report